1998
Thrombolytic agents - an updated overview.
Gulba, D.C., Bode, C., Runge, M.S. and Huber, K.
Fibrinolysis & Proteolysis 12
(Suppl 2): 39-58.
1 September 1998
Platelet inhibition: new agents, new strategies, new trials.
Gulba, D.C., Huber, K., Moll, S. and Dietz, R.
Fibrinolysis & Proteolysis 12
(Suppl 2): 13-23.
1 September 1998
Acute coronary syndromes: recent achievements and future aspects.
Huber, K., Nikfardjam, M., Christ, G., Gottsauner-Wolf, M., Muellner, M. and Gulba, D.
Fibrinolysis & Proteolysis 12
(Suppl 2): 67-89.
1 September 1998
1997
Update on the toxicology and pharmacology of rDSPA alpha 1 (Bat-PA) in animals and humans.
Gulba, D.C., Praus, M., Dechend, R., Hauck, S., Mahler, M., Zitvz, R., Baldus, B., Mueller, W. and Dietz, R.
Fibrinolysis & Proteolysis 11 Suppl. 2
: 55-62.
1 August 1997
Signal transduction via urokinase receptor: is a transmembrane adapter molecule really necessary?
Dumler, I., Hucho, F. and Gulba, D.
Fibrinolysis & Proteolysis Suppl. 11
: 165-169.
1 January 1997
New antithrombotic agents: an overview.
Windstetter, U., Huber, K. and Gulba, D.
Fibrinolysis & Proteolysis 11 Suppl.
: 85-96.
1 January 1997
1995
The problem of reocclusion and restenosis - clinical aspects.
Dechend, R., Gulba, D., Hauck, S. and Dietz, R.
Fibrinolysis & Proteolysis 9
(Suppl:1): 48-52.
1 January 1995
DSPA alpha - properties of the plasminogen activators of the vampire bat desmodus rotundus.
Gulba, D., Praus, M. and Witt, W.
Fibrinolysis & Proteolysis 9
(Suppl:1): 91-96.
1 January 1995
Nierenarterien-Embolie - Thrombloyse mit rt-RA.
Gulba, D.C.
Fibrinolysis & Proteolysis 3
: 15-17.
1 January 1995
Continuous 3-dimensional vectorcardiography, a valuable tool for online ischemia monitoring.
Hauck, S., Friedrich, M., Dechend, R., Gulba, D. and Dietz, R.
Fibrinolysis & Proteolysis 9
(Suppl:1): 114-120.
1 January 1995
Thrombolysis - a rapidly moving target of antithrombotic therapy: a preface.
Huber, K., Bode, C. and Gulba, D.
Fibrinolysis & Proteolysis 9
(Suppl:1): 1-2.
1 January 1995
Prevention of postoperative thromboembolic complications in a patient with budd-chiari syndrome and acquired protein c deficiency by short-term administration of protein c concentrates.
Schueler, A., Gulba, D., Sosada, M., Ringe, B., Pichlmayr, R. and Manns, M.
Fibrinolysis & Proteolysis 9
(Suppl:1): 129-132.
1 January 1995
Analysis of the human tissue-type plasminogen activator gene promoter activitor gene promoter activity during embryogenesis of transgenic mice and rats.
Theuring, F., Aguzzi, A., Turner, J.D., Kropp, C., Hoffmann, S. and Schleuning, W.D.
Fibrinolysis & Proteolysis 9
(5): 277-287.
1 January 1995
1994
Effects of low-molecular weight and high-molecular weight heparin on the intrinsic and extrinsic endogenous fibrinolytic system.
Dechend, R., Hauck, S., Eichhorn, J., Goedecke, W., Praus, M., Schulz-Menger, J., Barthels, M., Dietz, R. and Gulba, D.
Fibrinolysis & Proteolysis 8 Suppl. 2
: 71-74.
1 January 1994
Fragmentation pattern of fibrinogen during thrombolysis in acute myocardial infaction with fibrin-specific plasminogen activators - detection of high-molecular weight fibrinogen degradation products.
Dechend, R., Thode, H., Mueller, T., Eisert, W.E., Dietz, R. and Gulba, D.
Fibrinolysis & Proteolysis 8 Suppl. 2
: 102-104.
1 January 1994
Transgenic mice carrying a human t-PA promoter-lacZ reporter gene: A model for the study of pharmacological modulation of fibrinolytic potential.
Theuring, F., Kooistra, T. and Schleuning, W.D.
Fibrinolysis & Proteolysis 8
: 16-18.
1 January 1994
This list was generated on Fri Dec 20 21:55:11 2024 UTC.